

Sub I 7. (Reiterated) The method of claim 6, wherein the method does not comprise selecting an agent based on its ability to inhibit FKBP-12 rotamase activity.

Please cancel claims 9 and 10, without prejudice to renewal.

G2 Sub H1 11. (Twice Amended) The method of claim 6, further comprising selecting a FK506 analog that does not inhibit rotamase activity.

G3 15. (Twice Amended) The method of claim 6, wherein the assay for activity in promoting nerve cell growth comprises exposing a cell to the selected FK506 analog and determining if neurite outgrowth is promoted.

Please cancel claims 16-17, without prejudice to renewal.

20. (Twice Amended) A method of identifying a FK506 analog that stimulates nerve cell growth, the method comprising:

G4 screening a plurality of FK506 analogs for binding to FKBP-12;

selecting one or more FK506 analogs of interest that has a K_d for FKBP-12 of at least 100 μM ; and

assaying of one or more of the analogs of interest for activity in promoting nerve cell growth.

Please cancel claim 21, without prejudice to renewal.

REMARKS

Claims 9-10, 16-17 and 21 are canceled herein without prejudice to renewal. Claims 6, 11 and 20 are amended herein. Support for the amending language of claims 6 and 20 can be found